<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02452489</url>
  </required_header>
  <id_info>
    <org_study_id>ChangchunUCM02</org_study_id>
    <nct_id>NCT02452489</nct_id>
  </id_info>
  <brief_title>Different Acupoints Compatibility Difference of the Effect of Treatment of the Diabetic Gastroparesis</brief_title>
  <official_title>Scheme Optimization of Acupoints Compatibility and Influence Factors of the Effect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changchun University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hengyang Traditional Chinese Medicine Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second People's Hospital of Hunan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Changchun University of Chinese Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With Diabetic gastroparesis as the research object, by the method of multi-center RCT and&#xD;
      single cavity and different acupuncture acupoints compatibility treatment of diabetic&#xD;
      gastroparesis, the inspection of gastric emptying, gastric dynamic inspection, such as&#xD;
      validity checking means, for single cavity with different acupoints compatibility evaluate&#xD;
      clinical efficacy of treatment of diabetic gastroparesis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to establish a spectrum of acupoints compatibility of the law, is clear about the&#xD;
      factors affecting the compatibility effect of acupoints, the formation of strong operability&#xD;
      of acupoints compatibility optimization evaluation method, the project choice of the clinical&#xD;
      acupuncture and moxibustion have curative effect of diabetic gastroparesis as the&#xD;
      breakthrough point of the study, carried out clinical multi-center RCT research, through&#xD;
      objective and scientific evaluation method, comparing the effect of different acupoints&#xD;
      compatibility.&#xD;
&#xD;
      Diabetic gastroparesis in clinical common disease, frequently-occurring disease, acupuncture&#xD;
      curative effect is distinct, disease diagnosis, curative effect evaluation standard. Previous&#xD;
      clinical data also show that the diabetic gastroparesis is acupuncture clinical diseases.&#xD;
      This project by diabetic gastroparesis as the research object, research to better guide&#xD;
      clinical practice, improve the clinical curative effect, promote acupuncture of the&#xD;
      inheritance and innovation, promote scientification of acupuncture and moxibustion,&#xD;
      modernization and internationalization, and will have broad prospect of application and&#xD;
      significant scientific research value.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastroparesis Symptoms Rating Scale(GCSI)</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FBG(fasting blood-glucose)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPG(postprandial blood sugar)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying check by Color ultrasonography</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric emptying check by X rays</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short form 36 health survey(SF-36)</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating anxiety scale(SAS)</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Rating Depression Scale(SDS)</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">99</enrollment>
  <condition>Diabetic Gastroparesis</condition>
  <arm_group>
    <arm_group_label>Single point group (Zhongwan)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be acupuncture with Zhongwan(RN12).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination of He-Mu points group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in Control group,will be acupuncture with at the junction of deltoid and biceps.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>acupuncture</intervention_name>
    <description>Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.</description>
    <arm_group_label>Single point group (Zhongwan)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>acupuncture</intervention_name>
    <description>Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.</description>
    <arm_group_label>Combination of He-Mu points group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>acupuncture</intervention_name>
    <description>Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of Diabetic Gastroparesis;&#xD;
&#xD;
          -  Aged 18-60 (including 18 and 60);&#xD;
&#xD;
          -  Fasting venous blood sugar ≤7.8mmol/L,2-hour post-meal blood glucose ≤ 13.6mmol/ L;&#xD;
&#xD;
          -  Diabetes more than 3 years;&#xD;
&#xD;
          -  Diet and exercise therapy or diet movement and exercise therapy based on the use of&#xD;
             hypoglycemic drugs (except alpha glycosidase inhibitor) treatment, dose stable at&#xD;
             least more than 3 months;&#xD;
&#xD;
          -  Rounding out the top three months did not participate in any clinical subjects;&#xD;
&#xD;
          -  Sign the informed consent and voluntary to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with reflux esophagitis;&#xD;
&#xD;
          -  Postoperative gastroparesis patients;&#xD;
&#xD;
          -  Ketoacidosis, non ketosis acute complications such as hypertonic coma;&#xD;
&#xD;
          -  Patients with acute cardiovascular disease, with severe trauma or surgery, severe&#xD;
             infections, pregnancy or breast-feeding women;&#xD;
&#xD;
          -  Patients with myocardial infa,acute coronary syndrome (ACS),coronary&#xD;
             revascularization;&#xD;
&#xD;
          -  Patients with severe liver disease, or the AST and/or ALT 2 times higher than normal&#xD;
             ceiling;&#xD;
&#xD;
          -  Patients with Serum creatinine kidney damage, more than 140 umol/L;&#xD;
&#xD;
          -  Patients with obvious blood system diseases (either in person are not to be included&#xD;
             in the item: Hb: men &lt; 110 g/L, women &lt; 100 g/L, the WBC &lt; 3.5×109/L/L, PLT &lt;&#xD;
             80×109/L);&#xD;
&#xD;
          -  Patients's systolic pressure≥180mmHg,Patients's diastolic pressure≥100mmHg;&#xD;
&#xD;
          -  Patients with Advanced malignant tumor or other serious wasting disease, infection and&#xD;
             bleeding;&#xD;
&#xD;
          -  Endoscopy has the organic lesion such as peptic ulcer;&#xD;
&#xD;
          -  Disorders or do not fit the person and the growing experiment condition or severe&#xD;
             complications;&#xD;
&#xD;
          -  Nearly four weeks of alpha glycosidase inhibitor drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fuchun Wang, master</last_name>
    <role>Study Chair</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tie Li, Ph.D</last_name>
    <phone>+86 0431 86714973</phone>
    <email>zusanli_1999@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital To Changchun University of Chinese Medicine</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tie Li, Ph.D</last_name>
      <phone>+86 0431 86714973</phone>
      <email>zusanli_1999@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2015</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changchun University of Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Tie Li</investigator_full_name>
    <investigator_title>973 project management deputy director of the office</investigator_title>
  </responsible_party>
  <keyword>Different acupoints compatibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

